Physician profile
Ralph Silverman
NPI 1801899141
$5,403.70
in general payments reported to CMS, 2019-2025
19 companies · $3,034 in 2025
The $3,034 reported for 2025 was more than what 84% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $247 · 2021: $340 · 2022: $378 · 2023: $409 · 2024: $452 · 2025: $3,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,223 · Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,222.64 |
| Food and Beverage | $672.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,242.63 | 2019-2025 | |
| Medtronic, INC. | $577.45 | 2021-2023 | Interstim, Signia |
| Otsuka America Pharmaceutical, INC. | $389.54 | 2019-2021 | |
| Vifor Pharma, INC. | $285.47 | 2019-2022 | |
| Ethicon US, LLC | $229.82 | 2024 | Echelon; Endopath, Echelon Circular |
| Tela Bio, INC. | $159.27 | 2023 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Opko Pharmaceuticals, LLC | $140.93 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $66.58 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $54.92 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.53 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.63 | 2020-2021 | |
| Conmed Corporation | $33.66 | 2025 | Visiclear |
| Shire North American Group INC | $30.76 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $27.45 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $25.38 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $18.33 | 2021 | |
| Daiichi Sankyo INC. | $15.88 | 2022 | |
| Braintree Laboratories, INC. | $14.39 | 2023 | Sutab |
| Astrazeneca Pharmaceuticals Lp | $13.08 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.